Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19718856 | 0.82 | ALDH1A1 (0.56) | HSD17B10ALDH1A1MAPTCA2HSD11B1 | |
| SCHEMBL1082701 | 0.82 | ALDH1A1 (0.56) | HSD17B10ALDH1A1MAPTCA2HSD11B1 | |
| SCHEMBL26081355 | 0.80 | ALDH1A1 (0.55) | HSD17B10ALDH1A1MAPTCA2HSD11B1 | |
| SCHEMBL14801937 | 0.78 | ALDH1A1 (0.44) | HSD17B10ALDH1A1MAPTHSD11B1EPHX1 | |
| SCHEMBL11635652 | 0.78 | ALDH1A1 (0.53) | HSD17B10ALDH1A1MAPTCA2EPHX1 | |
| SCHEMBL2526511 | 0.78 | ALDH1A1 (0.53) | HSD17B10ALDH1A1MAPTCA2HSD11B1 | |
| SCHEMBL14696638 | 0.77 | ALDH1A1 (0.51) | HSD17B10ALDH1A1MAPTCA2HSD11B1 | |
| SCHEMBL12442332 | 0.75 | ALDH1A1 (0.42) | HSD17B10ALDH1A1MAPTCA2HSD11B1 | |
| SCHEMBL10532688 | 0.74 | CYP17A1 (0.53) | HSD17B10ALDH1A1MAPTCA2GLA | |
| Ammonia Solution, Strong SCHEMBL11636588 | 0.74 | HSD17B10 (0.50) | HSD17B10ALDH1A1MAPTCA2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105218483-A | Be used for the treatment of the cell death inducer of cancer and immunity and autoimmune disorder | ABBVIE INC | 2016-01-06 | — | — | CN | disclosed |
| CN-102947283-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE (US) | 2015-10-07 | — | — | CN | disclosed |
| CN-102947283-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2013-02-27 | — | — | CN | disclosed |
| CN-101497599-B | Monomer, resin, resist composition using the resin, and method producing semiconductor device using the resist composition | FUJITSU LTD | 2012-09-05 | — | — | CN | disclosed |
| CN-101497599-A | Monomer, resin, resist composition using the resin, and method producing semiconductor device using the resist composition | FUJITSU LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| US-7488832-B2 | e.g. N-[amino(imino)methyl]-2-[2-(4-phenoxyphenyl)-5-phenyl-1H-pyrrol-1-yl]acetamide; beta -amyloid deposits and neurofibrillary tangles; cognition activator, neurodegenerative diseases; Alzheimer's disease, Down's syndrome | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080287424-A1 | AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS | WYETH (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1848692-A1 | AZOLYLACYLGUANIDINES AS ß-SECRETASE INHIBITORS | Wyeth (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006088711-A1 | AZOLYLACYLGUANIDINES AS β-SECRETASE INHIBITORS | WYETH (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183790-A1 | Azolylacylguanidines as beta-secretase inhibitors | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287424-A1 | AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS | BACE1, BACE2, APP | HSD17B10 933/4885ALDH1A1 360/4885MAPT 30/4885 |
| US-20060183790-A1 | Azolylacylguanidines as beta-secretase inhibitors | BACE1, BACE2, APP | HSD17B10 933/4885ALDH1A1 360/4885MAPT 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.